What is Chengdu Kanghua Biological Products Co., Ltd.'s (300841.SZ) StockRank?

MoatMap's StockRank for Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) is 67/100, with a Buy signal. This is a composite score combining Quality (74), Value (43), and Momentum (38) factor ranks across MoatMap's 19,000+ stock universe.

Does Chengdu Kanghua Biological Products Co., Ltd. have an economic moat?

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) has a Quality factor score of 74/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Chengdu Kanghua Biological Products Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Chengdu Kanghua Biological Products Co., Ltd. in?

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300841.SZ

BUYREMOVE

Chengdu Kanghua Biological Products Co., Ltd. · Healthcare · China · $917M · Avg Vol: $15M/d

StockRank

P/E (TTM)

26.3x

ROE

6.4%

D/E

0.0x

Dividend %

1.1%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Chengdu Kanghua Biological is a vaccine developer rather than a pure-play CDMO. While it has decent quality metrics, it does not benefit from the systemic pricing power shift occurring in validated contract manufacturing organizations.

COMPANY DESCRIPTION

Chengdu Kanghua Biological Products Co., Ltd. is a premier Chinese biotechnology company specializing in the research, development, and commercialization of human vaccines. The company's primary competitive moat is its status as the first domestic manufacturer of the freeze-dried human diploid cell rabies vaccine, which is widely considered the gold standard for safety and efficacy. It operates as a high-margin, niche leader in the Chinese biopharmaceutical sector with strong brand equity.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	214M	233M	212M	172M	-7.0%
EPS	0.66	0.56	0.45	0.25	-27.6%
Shares	135M	135M	133M	130M	-3.5%
Debt	19M	28M	28M	21M	3.5%
Equity	455M	519M	510M	523M	4.8%
Op CF	29M	85M	85M	56M	24.9%
Inv CF	-61M	-24M	-51M	22M	—
Fin CF	-11M	-1M	-70M	-27M	—

PRICE (1M)-19.7%

SMA 50SMA 200

$6.78

RSI (14)

34.8

52W High

$13.79

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

7.4%64.8

ROE

6.4%60.6

GP/Assets

27.3%60.8

Op. Margin

17.5%78.6

FCF/Assets

6.7%77.4

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.01x89.5

Current Ratio

7.89x82.3

Value

P/E (TTM)

26.3x43.3

EV/EBITDA

14.6x28.5

P/FCF

157.3x52.3

P/B

1.7x62.4

P/S

5.0x41.7

Div Yield

1.1%30.1

Momentum

52W High %

49%22.5

RS 6M

-51%21.4

SMA 50/200

0.78x11.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+252%90.7

Q Growth

32%69.8

FUNDAMENTALS

Market Cap

$917M

P/E (Forward)

7.5x

Gross Margin

90.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300841.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300841.SZ	Chengdu Kanghua Biological Products Co., Ltd.(you)	$917M	67	BUY
688105.SS	Nanjing Vazyme Biotech Co., Ltd	$1.1B	63	HOLD
688315.SS	Novogene Co., Ltd.	$870M	60	HOLD
301047.SZ	Sino Biological,Inc.	$1.1B	70	BUY
688046.SS	GemPharmatech Co., Ltd.	$1.2B	70	BUY
688253.SS	Innovita Biological Technology Co., Ltd.	$1.1B	58	HOLD
000990.SZ	Chengzhi Co., Ltd.	$1.7B	63	HOLD
605116.SS	Aurisco Pharmaceutical Co.,Ltd.	$1.2B	56	HOLD
688526.SS	Wuhan Keqian Biology Co.,Ltd	$906M	83	STRONG BUY
603566.SS	Pulike Biological Engineering, Inc.	$543M	74	BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) — Stock Score Summary

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) has a MoatMap StockRank of 67/100 based on Quality (74/100), Value (43/100), and Momentum (38/100) factor scores. The current signal is BUY. Chengdu Kanghua Biological is a vaccine developer rather than a pure-play CDMO. While it has decent quality metrics, it does not benefit from the systemic pricing power shift occurring in validated contract manufacturing organizations.

Key Financial Metrics

Price	$6.78
Market Cap	$917M
P/E (TTM)	26.29
P/E (Forward)	7.48
Price/Book	1.67
Return on Equity	6.4%
Return on Invested Capital	7.4%
Debt/Equity	0.84
Gross Margin	90.9%
Operating Margin	17.5%
Revenue Growth	25.0%
Dividend Yield	1.1%
Free Cash Flow	$6M

Chengdu Kanghua Biological Products Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Chengdu Kanghua Biological Products Co., Ltd.’s (300841.SZ) StockRank?: MoatMap’s StockRank for Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) is 67/100, with a Buy signal. It is a composite of Quality (74), Value (43), and Momentum (38) factor ranks across MoatMap’s 19,000+ stock universe.
Does Chengdu Kanghua Biological Products Co., Ltd. have an economic moat?: Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) has a Quality factor score of 74/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Chengdu Kanghua Biological Products Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Chengdu Kanghua Biological Products Co., Ltd. in?: Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).